Search
for

    Glossary Bortezomib

    inhibits proteasomes to treat multiple myeloma and lymphoma

    Bortezomib, also known by the brand name Velcade, is a medication used primarily to treat multiple myeloma and mantle cell lymphoma. It works by inhibiting proteasomes, which are enzyme complexes that break down proteins in cells, thereby causing cancer cells to die. This targeted action helps to control the growth and spread of cancerous cells.

    Sort by

    Research 30 of 76

    1. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects Cutaneous and Ocular Toxicology · 2013 · 18 citations
    2. 440 Topical application of anti-cancer drug Bortezomib stimulates proliferation of follicular cells and induces expression of hair keratins via GATA-3 transcription factor 2016
    3. 증례 : 몸통의 다발성 판으로 나타난 Bortezomib에 의한 약물 발진 2예 대한피부과학회지 · 2016
    4. Proteasome Inhibitors: An Expanding Army Attacking a Unique Target Chemistry & biology · 2012 · 474 citations
    5. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer Journal of the American Academy of Dermatology · 2014 · 88 citations
    6. Alopecia in patients treated with molecularly targeted anticancer therapies Annals of Oncology · 2015 · 44 citations
    7. Drugs linked to blepharitis, meibomian gland dysfunction, and chalazion: a real-world, population-based pharmacovigilance analysis Eye · 2025 · 1 citations
    8. Cutis Verticis Gyrata Heralding a Diagnosis of Primary Systemic Amyloidosis in a Patient with Cardioembolic Stroke Annals of Indian Academy of Neurology · 2023 · 1 citations
    9. Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana Projeto: revista mensal de arquitetura · 2008
    10. Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database Scientific Reports · 2021 · 1 citations
    11. PC-SPES Studies Promising, But Manufacturer Shuts Down Oncology Times · 2002
    12. 69-Year-Old Man With Dysuria and Right Lower Abdominal Pain Mayo Clinic Proceedings · 2022
    13. EX VIVO DRUG SENSITIVITY EVALUATION OF A RARE ZMYM2::FGFR1+ LEUKEMIA PATIENT Wiadomości Lekarskie · 2024
    14. Protein degradation: expanding the toolbox to restrain cancer drug resistance Journal of Hematology & Oncology · 2023 · 7 citations
    15. Amyloid associated alopecia: A case report and review of the literature Dermatology Online Journal · 2025
    16. A novel mutation in the FERMT1 gene in a Spanish family with Kindler’s syndrome Journal of The European Academy of Dermatology and Venereology · 2009 · 8 citations
    17. Chemotherapy‐induced alopecia management: Clinical experience and practical advice Journal of Cosmetic Dermatology · 2017 · 48 citations
    18. The concealed side of caspases: beyond a killer of cells Cellular and Molecular Life Sciences · 2024 · 13 citations
    19. Sulforaphane promotes murine hair growth by accelerating the degradation of dihydrotestosterone Biochemical and Biophysical Research Communications · 2016 · 12 citations
    20. Drug eruptions in dermatology Expert Review of Dermatology · 2011 · 11 citations
    21. Sulforaphane, L-Menthol, and Dexpanthenol as a Novel Active Cosmetic Ingredient Composition for Relieving Hair Loss Symptoms Cosmetics · 2021 · 3 citations
    22. Dermatologic Adverse Events from Cancer Treatments Springer eBooks · 2018 · 2 citations
    23. Adverse Hair Reactions to New Targeted Therapies for Cancer Actas Dermo-Sifiliográficas · 2019 · 1 citations
    24. Cutaneous drug reactions Elsevier eBooks · 2010 · 1 citations
    25. A novel hairless highly immunodeficient mice model optimized for in vivo imaging Laboratory Animal Research · 2026
    26. Noval advance of histone modification in inflammatory skin diseases and related treatment methods Frontiers in immunology · 2024
    27. POSTĘP W DIAGNOZIE I LECZENIU STWARDNIENIA ROZSIANEGO Wiadomości Lekarskie · 2024
    28. PŁYNY- NIE ZA DUŻO, NIE ZA MAŁO, LECZ W SAM RAZ Wiadomości Lekarskie · 2024
    29. ONKOLOGIA OKULISTYCZNA WCZORAJ I DZIŚ Wiadomości Lekarskie · 2024
    30. AUTOLOGOUS FAT GRAFTING UPDATE. PRESENTATION OF OWN RESULTS IN FACIAL REGENERATION Wiadomości Lekarskie · 2024